Chloramphenicol induces abnormal differentiation and inhibits apoptosis in activated T cells

Cancer Research

Volumn 68, Issue 12, 2008, Pages 4875-4881

  Yuan, Zeng Rong ^a,b   Shi, Yufang ^a  

^a RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIBODY; CD7 ANTIGEN; CHLORAMPHENICOL; FAS LIGAND; T LYMPHOCYTE RECEPTOR; CD3 ANTIGEN; CYCLIN B; CYCLIN B1; MYC PROTEIN; PROTEIN P53; PROTEIN SYNTHESIS INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CARCINOGENESIS; CELL DEATH; CELL DIFFERENTIATION; CELL MATURATION; CELL SIZE; CELL STIMULATION; CONTROLLED STUDY; LYMPHATIC LEUKEMIA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION; ANIMAL; BAGG ALBINO MOUSE; CHEMICALLY INDUCED DISORDER; CYTOLOGY; DRUG EFFECT; FLOW CYTOMETRY; GENETICS; HUMAN; METABOLISM; NORTHERN BLOTTING; PATHOLOGY; REGULATORY T LYMPHOCYTE; SPLEEN; T LYMPHOCYTE;

ANIMALS; ANTIGENS, CD3; APOPTOSIS; BLOTTING, NORTHERN; CELL DIFFERENTIATION; CHLORAMPHENICOL; CYCLIN B; FLOW CYTOMETRY; HUMANS; MICE; MICE, INBRED BALB C; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTEIN SYNTHESIS INHIBITORS; PROTO-ONCOGENE PROTEINS C-MYC; SPLEEN; T-LYMPHOCYTES; T-LYMPHOCYTES, REGULATORY; TUMOR SUPPRESSOR PROTEIN P53;

EID: 49649099086     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-6061     Document Type: Article

References (45)

1. Pancharoen C, Chongthaleong A, Reinprayoon S, Thisyakorn U. Invasive pneumococcal infection and drug-resistant Streptococcus pneumoniae in Thai children. J Med Assoc Thai 2001;84:1246-50.
2. Seneviratne Rde S, Navasivayam P, Perera S, Wickremasinghe RS. Microbiology of cerebral abscess at the neurosurgical unit of the National Hospital of Sri Lanka. Ceylon Med J 2003;48:14-6.
3. Thabet L, Boutiba I, Kammoun A, et al. [Epidemiologic profile of Haemophilus influenzae infection in Tunisia]. Tunis Med 2002;80:469-72.
4. Sirisanthana V, Puthanakit T, Sirisanthana T. Epidemiologic, clinical and laboratory features of scrub typhus in thirty Thai children. Pediatr Infect Dis J 2003;22:341-5.
5. Duke T, Michael A, Mokela D, Wal T, Reeder J. Chloramphenicol or ceftriaxone, or both, as treatment for meningitis in developing countries? Arch Dis Child 2003;88:536-9.
6. Muhe L. Managing pneumonia. Child Health Dialogue 1996;13:3-4.
7. Traversa G, Menniti-Ippolito F, Da Cas R, Mele A, Pulsoni A, Mandelli F. Drug use and acute leukemia. Pharmacoepidemiol Drug Saf 1998;7:113-23.
8. el-Mofty MM, Abdelmeguid NE, Sadek IA, Essawy AE, Aleem EA. Induction of leukaemia in chloramphenicol-treated toads. East Mediterr Health J 2000;6:1026-34.
9. Gomez-Casares MT, Vaque JP, Lemes A, Molero T, Delgado MD, Leon J. C-myc expression in cell lines derived from chronic myeloid leukemia. Haematologica 2004;89:241-3.
10. Handa H, Hegde UP, Kotelnikov VM, et al. Bcl-2 and c-myc expression, cell cycle kinetics and apoptosis during the progression of chronic myelogenous leukemia from diagnosis to blastic phase. Leuk Res 1997;21:479-89.
11. Lens D, De Schouwer PJ, Hamoudi RA, et al. p53 abnormalities in B-cell prolymphocytic leukemia. Blood 1997;89:2015-23.
12. Lam V, McPherson JP, Salmena L, et al. p53 gene status and chemosensitivity of childhood acute lymphoblastic leukemia cells to adriamycin. Leuk Res 1999;23: 871-80.
13. Leonard DG, Travis LB, Addya K, et al. p53 mutations in leukemia and myelodysplastic syndrome after ovarian cancer. Clin Cancer Res 2002;8:973-85.
14. Viallard JF, Lacombe F, Dupouy M, Ferry H, Belloc F, Reiffers J. Different expression profiles of human cyclin B1 in normal PHA-stimulated T lymphocytes and leukemic T cells. Cytometry 2000;39:117-25.
15. Shen M, Feng Y, Gao C, et al. Detection of cyclin b1 expression in G(1)-phase cancer cell lines and cancer tissues by postsorting Western blot analysis. Cancer Res 2004;64:1607-10.
16. Yu M, Zhan Q, Finn OJ. Immune recognition of cyclin B1 as a tumor antigen is a result of its overexpression in human tumors that is caused by non-functional p53. Mol Immunol 2002;38:981-7.
17. Shen M, Feng Y, Gao C, Tao D, Gong J. [Unscheduled expression of cyclin B1 in G(1)-phase among cultured and clinical tumor cells]. Zhonghua Zhong Liu Za Zhi 2002;24:215-8.
18. Viallard JF, Lacombe F, Dupouy M, Ferry H, Belloc F, Reiffers J. Flowcytometr y study of human cyclin B1 and cyclin E expression in leukemic cell lines: cell cycle kinetics and cell localization. Exp Cell Res 1999; 247:208-19.
19. Juan G, Traganos F, James WM, et al. Histone H3 phosphorylation and expression of cyclins A and B1 measured in individual cells during their progression through G2 and mitosis. Cytometry 1998;32:71-7.
20. Gasparotto D, Maestro R, Piccinin S, et al. Overexpression of CDC25A and CDC25B in head and neck cancers. Cancer Res 1997;57:2366-8.
21. Wu W, Fan YH, Kemp BL, Walsh G, Mao L. Overexpression of cdc25A and cdc25B is frequent in primary non-small cell lung cancer but is not associated with overexpression of c-myc. Cancer Res 1998;58:4082-5.
22. Bernardi R, Liebermann DA, Hoffman B. Cdc25A stability is controlled by the ubiquitin-proteasome pathway during cell cycle progression and terminal differentiation. Oncogene 2000;19:2447-54.
23. Galaktionov K, Chen X, Beach D. Cdc25 cell-cycle phosphatase as a target of c-myc. Nature 1996;382: 511-7.
24. Rose MG, Berliner N. T-cell large granular lymphocyte leukemia and related disorders. Oncologist 2004;9: 247-58.
25. Salih HR, Kiener PA. Alterations in Fas (CD 95/Apo-1) and Fas ligand (CD178) expression in acute promyelocytic leukemia during treatment with ATRA. Leuk Lymphoma 2004;45:55-9.
26. Murray AW. Recycling the cell cycle: cyclins revisited. Cell 2004;116:221-34.
27. Takizawa CG, Morgan DO. Control of mitosis by changes in the subcellular location of cyclin-B1-Cdk1 and Cdc25C. Curr Opin Cell Biol 2000;12:658-65.
28. Uhlmann F. Chromosome cohesion and separation: from men and molecules. Curr Biol 2003;13:R104-14.
29. 2/M arrest and skipping of mitosis in human prostate cell lines. Cancer Lett 1999;138:121-30.
30. Weingartner M, Criqui MC, Meszaros T, et al. Expression of a nondegradable cyclin B1 affects plant development and leads to endomitosis by inhibiting the formation of a phragmoplast. Plant cell 2004;16: 643-57.
31. Devadas S, Das J, Liu C, et al. Granzyme B is critical for T cell receptor-induced cell death of type 2 helper T cells. Immunity 2006;25:237-47.
32. Hoffmann P, Ermann J, Edinger M, Fathman CG, Strober S. Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrowtransplantation. J Exp Med 2002;196:389-99.
33. + regulatory T cells protects from lethal acute GVHD. Blood 2005;105: 2220-6.
34. + regulatory T cells. Blood 2005;105:4743-8.
35. Hering BJ, Kandaswamy R, Harmon JV, et al. Transplantation of cultured islets from two-layer preserved pancreases in type 1 diabetes with anti-CD3 antibody. Am J Transplant 2004;4:390-401.
36. + suppressor T cells: more questions than answers. Nat Rev Immunol 2002;2:389-400.
37. Shu XO, Gao YT, Linet MS, et al. Chloramphenicol use and childhood leukaemia in Shanghai. Lancet 1987; 2:934-7.
38. Shu XO, Gao YT, Brinton LA, et al. A population-based case-control study of childhood leukemia in Shanghai. Cancer 1988;62:635-44.
39. Cho NH, Kang S, Hong S, et al. Multinucleation of koilocytes is in fact multilobation and is related to aberration of the G2 checkpoint. J Clin Pathol 2005;58: 576-82.
40. 2-arrest to prevent mitotic entry with damaged DNA. Cell Cycle 2007;6:1147-52.
41. Jimenez JJ, Jimenez JG, Daghistani D, Yunis AA. Interaction of chloramphenicol and metabolites with colony stimulating factors: possible role in chloramphenicol-induced bone marrow injury. Am J Med Sci 1990;300:350-3.
42. Issaragrisil S, Kaufman DW, Anderson T, et al. Low drug attributability of aplastic anemia in Thailand. The Aplastic Anemia Study Group. Blood 1997;89:4034-9.
43. Doody MM, Linet MS, Glass AG, et al. Risks of non-Hodgkin's lymphoma, multiple myeloma, and leukemia associated with common medications. Epidemiology 1996;7:131-9.
44. Zheng W, Linet MS, Shu XO, Pan RP, Gao YT, Fraumeni JF, Jr. Prior medical conditions and the risk of adult leukemia in Shanghai, People's Republic of China. Cancer Causes Control 1993;4:361-8.
45. Bhoopalam N, Price K, Norgello H, Barone-Varelas J, Fried W. Busulfan and chloramphenicol induced T cell lymphoma: cell surface characteristics and functional properties. Clin Exp Immunol 1986;64:646-55.